Kite, a Gilead (GILD) Company, announced real-world data evaluating the safety and effectiveness of Yescarta for patients with relapsed/refractory large B-cell lymphoma assigned to treatment in an outpatient setting versus those assigned to an inpatient setting in a hospital. The analysis, based on data collected from the Center for International Blood and Marrow Transplant Research, CIBMTR, registry, observed that safety and effectiveness outcomes for people treated as outpatients were comparable to those patients who received treatment in a hospital. The results were shared in a presentation during the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting. Data were collected from the CIBMTR observational database. The final analysis assessed data on patients with R/R LBCL from 75 treatment centers, comparing 119 individuals who were assigned to receive Yescarta in the outpatient setting to 119 patients assigned to receive Yescarta in the inpatient setting. With a median follow-up of 12 months, no general differences were found between the 2 groups in the rates of cytokine release syndrome, neurologic events or immune effector cell-associated neurotoxicity syndrome grade greater than or equal to 3.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead announces data on Trodelvy plus Keytruda
- Gilead Sciences: Strong Market Position and Growth Potential Justify Buy Rating
- Here’s what Wall Street experts are saying about Salesforce ahead of earnings
- Gilead announces ASCENT-03 study meets primary endpoint
- Gilead put volume heavy and directionally bearish
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue